Physician profile
Ronald Schechter
NPI 1053321851
$7,870.32
in general payments reported to CMS, 2019-2025
34 companies · $52.23 in 2025
The $52.23 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,816 · 2020: $563 · 2021: $601 · 2022: $1,762 · 2023: $1,974 · 2024: $1,101 · 2025: $52.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $931.42 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $897.91 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $710.88 | 2019-2025 | |
| Edwards Lifesciences Corporation | $687.12 | 2019-2024 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $595.56 | 2019-2024 | Xarelto |
| Medtronic, INC. | $592.10 | 2021-2024 | Onyx Frontier |
| Amgen INC. | $467.97 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.96 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $305.77 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.05 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $209.48 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $208.39 | 2022-2024 | Onpattro |
| Amarin Pharma, INC. | $206.56 | 2019-2023 | |
| Novo Nordisk INC | $193.66 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Atricure, INC. | $145.57 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $130.01 | 2022-2024 | Mitraclip |
| Abiomed | $113.91 | 2020 | |
| Irhythm Technologies, INC. | $104.60 | 2019-2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $83.86 | 2019 | |
| Gilead Sciences, INC. | $74.00 | 2019 | |
| Philips North America LLC | $71.91 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Esperion Therapeutics, INC. | $68.95 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $56.22 | 2022-2024 | Verquvo |
| Kiniksa Pharmaceuticals, Ltd. | $53.24 | 2022 | |
| Boston Scientific Corporation | $50.51 | 2024 | Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor |
| Lexicon Pharmaceuticals, INC. | $47.52 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $43.51 | 2023-2024 | Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $36.03 | 2023 | |
| Scpharmaceuticals INC. | $35.94 | 2023 | |
| Biotronik INC. | $30.22 | 2019-2021 | |
| Medtronic Vascular, INC. | $27.73 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.99 | 2019 | |
| Preventice Services, LLC | $15.62 | 2019 | |
| Elutia, INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.